BVF
Latest statistics and disclosures from BVF's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, KYMR, RVMD, FDMT, GHRS, and represent 47.53% of BVF's stock portfolio.
- Added to shares of these 7 stocks: Cg Oncology (+$83M), TYRA (+$32M), IMUX (+$12M), ALLK (+$10M), SABS, UNCY, DCTH.
- Started 3 new stock positions in Cg Oncology, SABS, IMUX.
- Reduced shares in these 10 stocks: AXSM (-$158M), MRUS (-$71M), CNTA (-$70M), JANX (-$63M), PTGX (-$58M), KURA (-$55M), LXRX (-$55M), RLAY (-$44M), XENE (-$41M), SLN (-$26M).
- Sold out of its positions in SYRE, AXSM, CNTA, IMVT, ITOS, Rain Therapeutics, RLAY, SAB Biotherapeutics, SLN, STRO. XENE.
- BVF was a net seller of stock by $-603M.
- BVF has $3.6B in assets under management (AUM), dropping by -8.97%.
- Central Index Key (CIK): 0001056807
Tip: Access up to 7 years of quarterly data
Positions held by BVF consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BVF
BVF holds 62 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 30.0 | $1.1B | 22M | 50.23 |
|
|
| Kymera Therapeutics (KYMR) | 5.7 | $208M | 5.2M | 40.20 |
|
|
| Revolution Medicines (RVMD) | 5.3 | $193M | 6.0M | 32.23 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 3.4 | $125M | -2% | 3.9M | 31.86 |
|
| Gh Research Ordinary Shares (GHRS) | 3.0 | $111M | 10M | 10.66 |
|
|
| Janux Therapeutics (JANX) | 3.0 | $110M | -36% | 2.9M | 37.65 |
|
| Mirum Pharmaceuticals (MIRM) | 3.0 | $110M | 4.4M | 25.12 |
|
|
| Protagonist Therapeutics (PTGX) | 3.0 | $109M | -34% | 3.8M | 28.93 |
|
| Ionis Pharmaceuticals (IONS) | 2.9 | $105M | 2.4M | 43.35 |
|
|
| Olema Pharmaceuticals (OLMA) | 2.8 | $103M | 9.1M | 11.32 |
|
|
| Kura Oncology (KURA) | 2.8 | $102M | -35% | 4.8M | 21.33 |
|
| Xoma Corp Del Com New (XOMA) | 2.4 | $87M | 3.6M | 24.05 |
|
|
| Cg Oncology | 2.3 | $83M | NEW | 1.9M | 43.90 |
|
| Tyra Biosciences (TYRA) | 2.1 | $76M | +70% | 4.7M | 16.40 |
|
| Essa Pharma Com New (EPIX) | 2.0 | $74M | 8.7M | 8.49 |
|
|
| Zymeworks Del (ZYME) | 1.7 | $62M | 5.9M | 10.52 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 1.6 | $60M | -2% | 1.9M | 32.20 |
|
| Cullinan Oncology (CGEM) | 1.5 | $55M | 3.2M | 17.04 |
|
|
| Merus N V (MRUS) | 1.5 | $53M | -57% | 1.2M | 45.03 |
|
| Ideaya Biosciences (IDYA) | 1.4 | $51M | -32% | 1.2M | 43.88 |
|
| Annexon (ANNX) | 1.4 | $50M | 7.0M | 7.17 |
|
|
| Repare Therapeutics Ord (RPTX) | 1.3 | $49M | 10M | 4.71 |
|
|
| 89bio (ETNB) | 1.3 | $47M | 4.0M | 11.64 |
|
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $45M | 1.9M | 23.80 |
|
|
| Ac Immune Sa SHS (ACIU) | 1.2 | $43M | 15M | 2.96 |
|
|
| Third Harmonic Bio (THRD) | 1.1 | $41M | 4.4M | 9.44 |
|
|
| Engene Holdings (ENGN) | 1.0 | $38M | 2.3M | 16.95 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $36M | 1.5M | 23.65 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.0 | $35M | 813k | 42.86 |
|
|
| Roivant Sciences SHS (ROIV) | 0.8 | $29M | 2.7M | 10.54 |
|
|
| Glycomimetics (GLYC) | 0.8 | $29M | 9.5M | 3.00 |
|
|
| Tscan Therapeutics (TCRX) | 0.7 | $24M | 3.0M | 7.94 |
|
|
| Allakos (ALLK) | 0.6 | $21M | +93% | 17M | 1.26 |
|
| Verastem Com New (VSTM) | 0.5 | $20M | 1.7M | 11.80 |
|
|
| Calliditas Therapeutics Ab Sponsered Ads (CALT) | 0.4 | $16M | 750k | 21.65 |
|
|
| Cytomx Therapeutics (CTMX) | 0.4 | $14M | 6.6M | 2.18 |
|
|
| Elevation Oncology (ELEV) | 0.3 | $12M | 2.3M | 5.13 |
|
|
| Ovid Therapeutics (OVID) | 0.3 | $12M | -43% | 3.9M | 3.05 |
|
| Immunic (IMUX) | 0.3 | $12M | NEW | 8.9M | 1.32 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $11M | 2.0M | 5.28 |
|
|
| Eledon Pharmaceuticals (ELDN) | 0.2 | $8.9M | 4.3M | 2.06 |
|
|
| Verve Therapeutics (VERV) | 0.2 | $8.6M | 650k | 13.28 |
|
|
| Ikena Oncology (IKNA) | 0.2 | $6.8M | 4.8M | 1.42 |
|
|
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.2 | $6.3M | 6.9M | 0.92 |
|
|
| Vigil Neuroscience (VIGL) | 0.2 | $6.2M | 1.8M | 3.41 |
|
|
| Delcath Sys Com New (DCTH) | 0.2 | $5.7M | +23% | 1.2M | 4.77 |
|
| Unicycive Therapeutics (UNCY) | 0.1 | $5.0M | +70% | 3.6M | 1.38 |
|
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.1 | $4.9M | 945k | 5.20 |
|
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $4.2M | NEW | 918k | 4.54 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.1 | $4.0M | -93% | 1.7M | 2.40 |
|
| An2 Therapeutics (ANTX) | 0.1 | $4.0M | -20% | 1.2M | 3.25 |
|
| Kronos Bio (KRON) | 0.1 | $3.8M | 2.9M | 1.30 |
|
|
| Pieris Pharmaceuticals (PIRS) | 0.1 | $3.8M | 21M | 0.18 |
|
|
| Viracta Therapeutics (VIRX) | 0.1 | $3.7M | 3.6M | 1.02 |
|
|
| Inventiva Sa Ads (IVA) | 0.1 | $2.5M | 686k | 3.62 |
|
|
| Forte Biosciences (FBRX) | 0.1 | $2.1M | 3.0M | 0.70 |
|
|
| Molecular Partners Ads (MOLN) | 0.0 | $1.7M | 443k | 3.88 |
|
|
| Molecular Templates Com New (MTEM) | 0.0 | $1.2M | 522k | 2.24 |
|
|
| Nls Pharmaceutics SHS (NLSP) | 0.0 | $1.0M | 5.7M | 0.18 |
|
|
| Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $646k | 1.0M | 0.62 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.0 | $643k | -73% | 361k | 1.78 |
|
| Rezolute Com New (RZLT) | 0.0 | $487k | 191k | 2.55 |
|
Past Filings by BVF
SEC 13F filings are viewable for BVF going back to 2010
- BVF 2024 Q1 filed May 15, 2024
- BVF 2023 Q4 filed Feb. 14, 2024
- BVF 2023 Q3 filed Nov. 14, 2023
- BVF 2023 Q2 filed Aug. 14, 2023
- BVF 2023 Q1 filed May 15, 2023
- BVF 2022 Q4 filed Feb. 14, 2023
- BVF 2022 Q3 filed Nov. 14, 2022
- BVF 2022 Q2 filed Aug. 15, 2022
- BVF 2022 Q1 filed May 16, 2022
- BVF 2021 Q4 filed Feb. 14, 2022
- BVF 2021 Q3 filed Nov. 15, 2021
- BVF 2021 Q2 filed Aug. 16, 2021
- BVF 2021 Q1 filed May 17, 2021
- BVF 2020 Q4 filed Feb. 12, 2021
- BVF 2020 Q3 filed Nov. 13, 2020
- BVF 2020 Q2 filed Aug. 14, 2020